Funding for this research was provided by:
U.S. National Library of Medicine (R00LM011595)
Received: 29 August 2019
Accepted: 4 February 2020
First Online: 12 March 2020
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board of Dana-Farber Harvard Cancer Center in Boston, Massachusetts, USA, protocol legacy 12–159. Clinical trials registration is with ExternalRef removed (ExternalRef removed), with registration number NCT01623349. All procedures involving human participants were carried out in accordance with the Declaration of Helsinki. Written, informed consent was obtained from patients or guardians before enrolment in the study.
: Not applicable.
: GMW reports grants from SU2C-AACR-DT0209, grants from Mary Kay Ash Foundation, grants from Ovarian Cancer Research Foundation, grants from Breast Cancer Alliance, grants from Breast Cancer Research Foundation, grants from NIH RO1 1R01CA226776–01, grants from Merck&Co, during the conduct of the study; In addition, Dr. Wulf has a patent Application 14/348810, Compositions and Methods for the Treatment of proliferative diseases pending, and a patent US 20090258352 A1, Pin1 as a marker for abnormal cell growth licensed to Cell Signaling; R&D Systems.UAM reports personal fees from Astrazeneca, personal fees from Myriad Genetics, personal fees from Clovis, personal fees from Merck, personal fees from Eli Lilly, personal fees from Mersana, personal fees from Geneos, personal fees from Fuji Film, from 2X Oncology, personal fees from Cerulean, personal fees from Immunogen, personal fees from Novartis, outside the submitted work .